Title (eng)
Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [??Ga]Ga-PSMA-11 PET/CT study
Author
Vincent Lotz
Holger Einspieler
David Haberl
Clemens Spielvogel
Dominik Amereller
Gero Kramer
Bernhard Grubmüller
Shahrokh Shariat
Alexander Haug
Marcus Hacker
Gerda Egger
Abstract (eng)
To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA levels and PSMA PET/CT findings in men with different stages of prostate cancer (PCa).122 PCa patients who underwent [??Ga]Ga-PSMA-11 PET/CT and plasma sampling (03/2019-08/2021) were analyzed. cfDNA was extracted, and a panel of 8 individual meth-ctDNA markers was queried. PET scans were qualitatively and quantitatively assessed. PSA and meth-ctDNA markers were compared to PET findings, and their relative prognostic value was evaluated.PSA discriminated best between negative and tumor-indicative PET scans in all (AUC 0.77) and hormone-sensitive (hsPC) patients (0.737). In castration-resistant PCa (CRPC), the meth-ctDNA marker KLF8 performed best (AUC 0.824). CHST11 differentiated best between non- and metastatic scans (AUC 0.705) overall, KLF8 best in hsPC and CRPC (AUC 0.662, 0.85). Several meth-ctDNA markers correlated low to moderate with
the tumor volume in all (5/8) and CRPC patients (6/8), while PSA levels correlated moderately to strongly with the tumor volume in all groups (all p?0.001). CRPC overall survival was independently associated with LDAH and PSA (p?=?0.0168, p?0.001).The studied meth-ctDNA markers are promising for the minimally-invasive detection and prognostication of CRPC but do not allow for clinical characterization of hsPC. Prospective studies are warranted for their use in therapy response and outcome prediction in CRPC and potential incremental value for PCa monitoring in PSA-low settings.
Keywords (eng)
HumansMalePositron Emission Tomography Computed Tomography MethodsAgedDNA Methylation GeneticsProstatic Neoplasms GeneticsProstatic Neoplasms BloodProstatic Neoplasms Diagnostic ImagingGallium RadioisotopesMiddle AgedBiomarkers, Tumor GeneticsBiomarkers, Tumor BloodProstate-Specific Antigen BloodProstate-Specific Antigen GeneticsGallium IsotopesCross-Sectional StudiesCirculating Tumor DNA GeneticsCirculating Tumor DNA BloodPrognosisAged, 80 and overProstatic NeoplasmsCastration-Resistant GeneticsCastration-Resistant BloodCastration-Resistant Diagnostic ImagingEdetic Acidanalogs & Derivatives
Type (eng)
Language
[eng]
Persistent identifier
Is in series
Title (eng)
Clinical Epigenetics
Volume
17
Issue
1
ISSN
1868-7083
Issued
2025
Number of pages
11
Publication
BMC
Version type (eng)
Date issued
2025
Access rights (eng)
License
Rights statement (eng)
© 2025. The Author(s).
- Citable links
Persistent identifier
DOI
https://phaidra.vetmeduni.ac.at/o:4004
https://doi.org/10.1186/s13148-025-01811-5 - Content
- DetailsObject typePDFDocumentFormatapplication/pdfCreated03.04.2025 08:12:31 UTC
- Usage statistics--
- This object is in collection
- Metadata
- Export formats